Home Ultrasound Gains Traction Among U.S. Maternal-Fetal Medicine Practices
Pulsenmore has secured another commercial engagement in the United States, continuing to build momentum following recent FDA clearance of its home ultrasound technology. The latest agreement brings Pulsenmore’s Early Screening home ultrasound services into TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice operating in Maryland.
The engagement reflects growing interest among U.S. providers in hybrid care models that combine at-home diagnostics with telehealth and in-clinic oversight, particularly in prenatal care where continuity and patient access are critical.
Integrating Home Ultrasound Into Physician-Led Care Models
Under the agreement, TLC Perinatal will incorporate Pulsenmore’s home ultrasound solution into its clinical workflow, allowing patients to perform physician-directed ultrasound scans at home. These scans are integrated into a broader care pathway that includes telehealth consultations and scheduled in-office visits, preserving clinical oversight while extending care beyond the clinic.
Pulsenmore’s platform is designed to give clinicians real-time visibility into patient scans while offering expectant mothers greater flexibility, reduced travel burden, and more continuous monitoring throughout pregnancy.
Why This Matters for U.S. Commercial Adoption
The engagement highlights a broader shift within maternal-fetal medicine toward patient-centric technologies that support remote monitoring without compromising diagnostic quality or clinical control. As healthcare systems continue to prioritize efficiency, access, and personalized care, home-based diagnostics are increasingly viewed as complementary rather than disruptive to traditional practice models.
TLC Perinatal manages approximately 2,000 pregnancies annually across its Maryland locations and is recognized for adopting new technologies that align with evolving clinical guidelines. The practice cited alignment with updated professional consensus supporting remote monitoring and personalized prenatal care as a key factor in adopting the technology.
Management Commentary Signals Early Commercial Validation
Pulsenmore’s leadership views the agreement as an early validation of U.S. market demand following regulatory clearance. Management emphasized that maternal-fetal medicine practices are actively seeking solutions that extend care into the home while maintaining physician control and evidence-based standards.
By embedding home ultrasound into existing workflows rather than replacing in-clinic diagnostics, Pulsenmore positions its platform as an additive tool that enhances both patient experience and clinical efficiency.
Broader Implications for Pulsenmore’s U.S. Strategy
This engagement follows a pattern of early-stage commercial adoption that suggests Pulsenmore’s technology is resonating with specialty practices focused on high-risk and diagnostic-intensive prenatal care. If adoption continues, the company could establish a differentiated niche within digital health by combining regulated medical imaging, telehealth infrastructure, and physician-directed home use.
As U.S. healthcare continues to shift toward hybrid delivery models, Pulsenmore’s approach may offer a scalable pathway for expanding prenatal care access without sacrificing clinical rigor.
Company Overview: Pulsenmore
Pulsenmore is focused on transforming maternal healthcare through home-use ultrasound technology that connects expectant mothers with healthcare providers remotely. The company’s platform combines advanced imaging with telemedicine infrastructure to support patient-centric prenatal care, improve continuity, and expand access while maintaining physician oversight.
Forward-looking information is subject to risks and uncertainties. Please read our full DISCLAIMER.
